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mmHg and 28*8 mmHg (p=O.528); systolic blood pressure 98+13mmHg and 
99+18mmHg (p=O.839); cardiac index 2.2+0.71Vmin/m2 and 2.1+0.61t/min/m2 (p=O.719). 
Kaplan-M&r sul~wal analysis showed a 60% reduction in the risk of death from any 
cause in the group treated with the combination of dobutemine and amiodarone, com- 
pared with the group treated with placebo and amiodarone (hazard ratio 0.403; 95% con- 
fidence interval 0.164-0.992, p=O.O48). The 1. and P-year survival rates were 69% and 
44%, in the dobutamine-treated group, versus 28% and 21%, respectively, in the pla- 
cebo-treated group (pcO.05 for both comparisons). Median su~lvals were 574 and 144 
days in Groups 2 and 1, respectively. At six months,‘the NYHA functional class was sig- 
nificantly Improved in the surviving patients of both groups. Conclusion: Long-term IDI 
combined with amiodarone, added to conventional treatment, improves survival of 
patients with severe CHF. 
the magnitude of that benefit is signficantly less than that observed in non-DM CHF pts. 
Therefore, all eligible pts wth symptomatic CHF, regardless of their DM status, should 
receive BBS for their prognostic benefits. 
All-Cause Mortabty: Diabetic vs Non-Diabetic Patients 
1085-76 Statin Therapy Is Associated With Improved Survival in 
lschemic and Nonischemic Heart Failure 
Tamara 8. Horwich, Michele A. Hamilton, Robb MacLellan, Jignesh Patel, Mary 
Lesniewski, Gregg C. Fonarow. University of California Los Angeles Medical Center, Los 
Angeles, CA 
Study 
BEST 
US CaNedilol 
CIBIS II 
COPERNICUS 
MERIT-HF 
Total 
Diabetics Non-Diabetics 
N RR 95% Cl r; RR 95% Cl 
964 0.95 0.80, 1.12 1744 0.89 0.77, 1.02 
307 0.37 0.14,0.93 772 0.44 0.23, 0.86 
312 0.81 0.52. 1.27 2335 0.68 0.55, 0.82 
589 0.68 0.46, 0.99 1700 0.67 0.53, 0.85 
984 0.82 0.58, 1.17 3007 0.58 0.46, 0.74 
3156 0.85 0.74,0.97 9558 0.72 0.65, 0.79 
1085-78 
Background: Although HMG CoA reductase inhibitors (statins) are known to decrease 
mortality in CHD, concern has been raised about potential negative effects in patients 
with heart failure (HF). The impact of statins on the progression of advanced HF has not 
been studied. 
Electrophysiologic Alterations Seen in Patients With 
Advanced Cardiac Failure After Angiotension 
Converting Enzyme Inhibitor Therapy 
Methods: We retrospectively studied a cohort of 251 pts with advanced HF referred for 
management and transplant evaluation. Pts without adequate documentation of medical 
regimen (n=33) were excluded from analysis. Survival free from death or urgent trans- 
plant was determined. 
Results: Mean age, EF, and total cholesterol (TC) were 52,25%, and 165 mg/dl, respec- 
tively. Fifty-one % of pts were on statin Rx. CAD was etiology of HF in 52% of patients, 
79% of whom were on statin Rx. In non-CAD HF pts. 28% were on statin Rx. Pis on 
statins were significantly older, and had higher rates of CAD, smoking, HTN, and DM. 
Treated and non-treated pts were similar in NYHA. LVEF, sex. BMI, TC, and HF medica- 
tions. Pts on statin Rx had improved survival over a 22 month follow-up (74% vs 56%, 
p=O.OOS). In subsets of pts without CAD and with TC cl65 mgidl. statins were similarly 
associated with Improved survival (p=O.O06. p=O.O4 respectively). Statin Rx was an inde- 
pendent predictor of improved survival after risk-adjustment for age. sex, EF, ACEI Rx. 
renal function, and serum cardiac troponin I. 
Petra S. Niemann, Roben Robbins, Julie Shinn, L. Bing Lien?, Sung Chun, Karen J 
Friday, Stanford University, Stanford, CA 
Background: Recognlzmg that mechanical circulatoty support induces changes in myo- 
cardial contractile function and intraventricular conduction (lVC),we examined whether 
there are changes iki IVC among heart failure patients with medical therapy only. Meth- 
ods: We studied 85 consecutive patients with New York Heart Association (NYHA) class 
2 and 3 heart failure undergoing medical therapy with ACE-Inhibitors and Beta-Blockers. 
Mean follow-up bme was 452 d +/- 186( median 374 d. range 128 to 745 d). Doppler 
Echocardiograms, ECGs and clinical symptom evaluations (NYHA) were obtained in 3 to 
6 months intewalls. Results: OF 85 oatients. 79 192%) showed IVC imorovement on cur- 
face ECG following medical therapy initiation (p< 0.01). Measured effects included a 
decrease in QRS duration from 115+/- 8 to 102 +I- 6 ms lo< 0.011 a decrease in absolute 
Conclusions: Statin Rx was associated with improved survival in ischemic and non- 
ischemic HF. Randomized trials are needed for confirmation of therapeutic benefit in 
non-ischemic HF. 
QT duration from 398 +/- 12 ms to 348 +I- 7 ms (p< 0.01) and a decrease in heart rate 
from 100.6 +/- 22.6 to 65 +/-I2 ms (p< 0.01). A LBBB pattern observed in 
32(37%)patlents prior to treatment initiation resolved in 14 (43%) patients after 6 months 
of medical therapy (p-z 0.01). Improved IVC on surface ECG and echocardlographic 
changes in myocardial structure and contractile function were positively correlated. (p-z 
0.01). All echocardlographic and electrocardiographic findings could be positivly corre- 
lated with clinical symptom improvement (NYHA class 1 and 2) in 83 ( 97%) patients (p-z 
0.01). Conclustions: Electrocardiographic changes seen with medical therapy aimed to 
improve myocardial contractility in heart failure patients demonstrate that IVC and repo- 
larization are dependent on longterm myocyte contractile function and possibly on 
altered calcium homeostasis. Improved left ventricular conduction and shortened cardiac 
action potential seen with ACE-Inhibitors therapy in heart failure seems therefore rather a 
longstanding Ion channel dependent process implicating variable gene expression in the 
failing heart than a pure mechanical response to hemodynamic loading conditions of the 
left ventricle. 
1085-77 Does the Magnitude of the Beneficial Effect of Beta- 
Blockers in Chronic Heart Failure Differ Between 
Diabetic and Nondiabetic Patients? A Meta-Analysis of 
All-Cause Mortality Outcomes From Major Chronic 
Heart Failure Beta-Blocker Trials 
Steven Haas, Theo Vos, Richard Gilbert, Henn/ Krum, Monash University, Melbourne, 
Australia 
Background: Diabetes mellitus (DM) is a frequent co-motiid association of patients (pts) 
with chronic heart failure (CHF). Although CHF pts derive benefit from beta-blockers 
(BBS), these agents are still thought by many to be contraindicated amongst DM pts and 
definitive data is lacking within this sub-group. We therefore performed a meta-analysis 
of major BB CHF trials to determine the benefits (or othenvise) of BBS in DM pts with 
CHF. 
Methods: All-cause mortality data concernmg DM pts were obtained from all completed 
CHF trials of >lOOO pts randomised to BB or placebo. Trials were identified via MEDLINE 
literature searches, manual reference checks & reference texts. Results were pooled 
using the ManteCHaenszel method. 
Results: 24.8% of pts were reported as having DM in the studies analyzed. DM pts had 
increased mortakty overall c.f. non-DM pts (annualised placebo mortality rate: DM 
17.0%. non-DM 13.9%; RR: 1.22, 95% Cl: 1.07-1.39). The Impact of BBS on mortality is 
summarised in the Table. 
BBS for CHF appears to be clinically beneficial I” DM es well as non-DM pts. However, 
the benficial impact of BBS is significantly greeter in non-DM pts, by calculation of risk dif- 
ference (PcO.05). 
Discussion: CHF pts wth DM appear to derive prognostic benefit from BBS, even though 
1085-79 Sustained Hemodynamic Benefit During Long-Term 
Positive lnotropic Infusion in Patients With Advanced 
Heart Failure 
Shnkanth P. Upadva. Forrester A. Lee, Clara I. Saldarriaga. Karin Nystrom, Stuart D. 
Katz, Yale University, New Haven, CT 
Background: Long term intravenous inotropic therapy is used as a bridge to cardiac 
transplantation in patients with end-stage chronic heart failure (CHF). We aimed to deter- 
mine whether acute hemodynamic benefits were sustained during chronic therapy. 
Methodr:We analyzed serial hemodynamic data from Plpatients with advanced CHF 
(mean age 55 ys, LVEF 21%) listed for cardiac transplantation and treated with continu- 
ous home infusions of positive inotropic agents. Rest hemodynamic data before, and at 
24 hours and 3-6 months after initiation of positive inotropic therapy were compared. Ino- 
tropic agent was dobutemine in 12 subjects (mean dose 4.5 mcglkglmin. range 2.5-7.5 
mcglkglmin), milrinone in 8 subjects (mean dose 0.44 mcglkglmin, range 0.375-0.55 mcl 
kglmin), and dopamine 3 mcg&$min in 1 subject. Oral neurohormonal antagonists were 
given es tolerated. Diuretics were adjusted to maintain a non-edematous state. 
Results: lnotropic therapy acutely improved rest hemodynamics charactewed by 
decreased PA pressure, PCWP and PVR and increased cardiac index (Table). During 
chronic therapy, further reductions in PA pressure and PVR were observed without 
change in PCWP or cardiac index. 
Conclusion: Acute beneficial hemodynamic effects of positive motropic therapy were 
sustained during chronic therapy in patients with advanced CHF awatlng cardiac trans- 
plantation. Tachyphylaxis was not a clinically important factor limiting the use of continu- 
ous positive inotropic agents in these patients. 
Rcstmg bemodynamics before and during positive inotmpx infusmn 
Right Pulmonary Pulmonary Pulmonary cardiac 
atrial artey mean caplillary wedge vascualr Index 
pressure (PAM) mm pressure resistance(PVR) (Cl) I/mn/ 
(RA) Hg (PCWP) wood units In2 
mm Hg 
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cious in Pts with NYHA class IV HF due to systolic dysfunction. Although these results 
must be treated with caution due to the small number of Pts studied, lack of effective 
therapies and the high risk of NYHA class IV HF suggests strong consideration for 
digoxin therapy in this population. 
Pre 11.4 +. 35+ 11 22.2 8 2 3.7 2 2 1.85+ 
inotrope 6 0.5 
Infusion 
24 hours 7.3+3 30.429 16.5 +8 2.5 f 1.7 2.8 _+O.g 
0” 
inotrope 
infusion 
3-6 months 3.9 3 + 27.5 9 _c 17.7-55 2.0 f 1.5 2.5 iO.5 
0” 
inotrope 
infusion 
1085-80 The Value of Dobutamine Stress Echo in Predicting 
Improvement in Left Ventricular Function in Patients 
With lschemic and Nonischemic Cardiomyopathy After 
One Year of Beta-Blocker Therapy 
Frank F. Seahatol. Dipan Shah, Silvia DiLuzio. David Belle, Mary1 R. Johnson, William G. 
Cotts, Jenny A. O’Donohue, Robert 0. Bonow, Mihai Gheorghiade, Vera H. Rigolin, 
Northwestern University, Chicago, IL 
Background: Beta-blockers reduce morbidity and mortality in chronic heart failure. How- 
war, the value of dobutamine stress echo (DSE) in predicting long-term global and seg- 
mental improvement in LV function in ischemic (IS) vs nonischemlc (NI) cardiomyopathy 
is not well defined. 
Methods: We studied 32 heart failure patients, 18 IS and 14 NI with LVEF< 35%. All 
were on stable doses of ACE-inhibitors. DSE was obtained prior to initiation of beta- 
blockers to define contractile reserve (CR). 2D echoes were bbtainad at baseline and 
after 12 months of carvedilol fw29. mean dose 47.0 +19.0 mold). metoorolol XL ln=2. 
_ I .  
mean dose 62.5 mg/d) or atenolol @=I, 12.5 mg/d). The left ventricle was divided into 16 
segments using the traditional ASE classification scheme. Contractility of each segment 
was assessed and an echo score (ES) was given. Each segment was classified as CR 
positive (+) or negative (-) based on presence or absence of improvement in ES 11 with 
low dose dobutamine (SmcgikgRnin) compared to baseline. The A EF was calculated as 
the difference in EF between baseline and 12 months. 
Results: See Fig. 
Conclusion: After 1 year of beta-blockers, EF and ES improve in both IS and NI patients 
irrespective of contractile reserve status. However, the magnitude of improvement IS 
greatest in NI patients with CR. 
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1085-81 Favorable Effects of Digoxin on Mortality and Morbidity 
in Patients With Class IV Congestive Heart Failure Due 
to Systolic Dysfunction: Retrospective Analysis of the 
DIG Study 
Kirkwood F. Adams, Jr., J. Herbert Patterson, Wendy A. Gattis, Christopher M. 
O’Connor. Todd A. Schwartz. Mihai Gheorahiade. Universitv of North Carolina - Chaoel _ 
Hill, Chapel Hill, NC 
Backgound: Previous small studies have suggested that digoxin exerts beneficial effects 
in severe symptomatic heart failure (HF), but data specifically in patients (Pts) with NYHA 
class IV and reduced ejection fraction are lacking. Therapeutic options are limited in 
NYHA class IV Pts, so effects of digoxin in this subset are of interest. 
Methods: The DIG Study. a large-scale prospective trial of the effect of digoxin on mor- 
bidity and mortality, included Pts with NYHA class IV. Data from this trial were analyzed 
to assess the effect of digoxln in Pts with NYHA class IV HF and reduced ejection frac- 
tions. 
Results: A total of 142 Pts with NYHA class IV symptoms at baseline and LVEF (45% I” 
the DIG Study were analyzed. As a group, these patients had severe left ventricular dys- 
function (mean LVEF 24 r 9.1%) with 1 year and 3 year survival rates of 68% and 41% 
respectively. Of these Pts, 76 were randomized to digoxin and 66 to placebo. Unadjusted 
swvival analysis demonstrated a trend toward a lower mortality rate in Pts randomized to 
digoxin (hazard ratio 0.68 with 95% confidence interval of 0.45 - 1.03. p = 0.068). Multi- 
variate, Cox analysis adjusting for baseline characteristics predictive of survival in this 
subset (prior digoxin therapy, systolic blood pressure, ischemic etiology, diabetes, and 
HF score), indicated that digoxin therapy was associated with better survival (hazard 
ratio 0.47 with 95% confidence intewal of 0.30 - 0.74, p = 0.001). Similar adjusted analy- 
sis found digoxin reduced the risk of the combined endpoint of mortality and time to first 
hospitalization for HF (hazard ratio 0.51 with 95% confidence interval 0.34 0.76, p = 
0.001). 
Conclusions. Retrospective analysis of the DIG Study results suggests digoxin is effica- 
1085-82 Sildenafil (Viagrafi) Improves Arterial Stiffness and 
Reduces Left Ventricular Load in Patients With 
Congestive Heart Failure 
Kozo Hirata, Charalambos Vlachopoulos, Audrey Adji, Michael F. O’Rourke, St. 
Vincent’s Clinic, University of New South Wales, Sydney, Australia 
Background: Sildenafil (S) is an effective drug for erectile dysfunction affecting the nitric 
oxide-cGMP pathway. The impairment of this pathway has been implicated in the patho- 
genesis of congestive heart failure (CHF). Arterial Stiffness and wave reflectlon are 
important determinants of left ventricular function, while wave reflection has also been 
inversely associated with exercise capacity. 
Methods: To investigate the effect of S on arterial stiffness and wave reflection in CHF 
we studied 20 patients (age 48-88 yrs) in NYHA class II or III (EF<35%), in a randomized. 
double-blind, placebo-controlled, cross-over design (50 mg of S and placebo). Carotid- 
femoral (aortic) and leg pulse wave velocity (PWV) ware measured as indices of arterial 
stiffness using a validated device (Complio@). Wave reflection was studied by maasur- 
ing augmentation index (Alx) using a validated system (SphygmoCorB) that employs 
high-fidelity arterial tonomeby and pulse wave analysis. 
Results: S was well tolerated with no side affects in any patient. S caused a decrease in 
left ventricular systolic pressure and on aortic pulse pressure by 13.9 mmHg and 4.8 
mmHg respectively (net sildenafil minus placebo effect, graph). Aorlic and leg PWV and 
Alx were also decreased by 0.89 m/set, 1.14 m/set, and 3.5% (graph). 
Conclusions: S leads to an improvement in arterial stiffness and to a reduction in left 
ventricular load in patients with CHF. This has important implications for cardiac perfor- 
mance and exercise capacity in such patients. 
1085-83 Serum Digoxin Concentration and the Efficacy of 
Digoxin Therapy in the Treatment of Heart Failure 
Saif S. Rathore, Jeptha P. Curtis, Yongfei Wang, Harlan M. Krumholz, Yale University 
School of Medicine, New Haven, CT 
Background: The association of serum digoxin (DIG) concentrations and all-cause mor- 
tality in patients with stable heart failure has not been assessed. 
Methods: We conducted an analysis of the Digitalis Investigation Group trial to assess 
variations in serum DIG concentration and their association with mortality. Because of a 
sex’DIG therapy interaction and the small number of women with measured serum DIG 
levels, analysis was restricted to male patients with an ejection fraction g5% (n=3,782). 
Patients randomized to DIG were divided into three groups based on their serum DIG 
concentration (SDC, in ng/mL) at 1 month - SDC a.8 (n=572), SDC 0.9 to 1 .l (n=322). 
and SDC _>I .2 (n=277) - and compared with patients randomized to placebo (n=2,811). 
Multivariable Cox proportional hazards analysis adjusting for age, renal function, LVEF, 
NYHA class, other patient characteristics, and medical therapy was conducted to assess 
the assoclabon of SDC and all-cause mortality (mean follow-up: 37 months). 
Results: Mortality rates were similar for patients randomized to placebo and DIG (36.2% 
vs. 36.6%. P=O.80). However, higher SDCs were associated with increased crude mor- 
tallty rates (SDC a.8 29.9%; SDC 0.9 to 1 .I 38.8%; SDC 21.2 48.0%, P<O.OOl for 
trend). Patients with SDC a.8 had a 6.3% (95% Cl 2.1%, 10.5%) lower all-cause mortal- 
ity rate than patients randomized to placebo. DIG was not associated with a reduction in 
all-cause mortality rates among patients with SDC 0.9 to 1.1 (2.6%. 95% Cl -3.O%, 
8.3%), while patients with SDC 21.2 had an 11.8% (95% Cl 5.7%, 18.0%) higher abso- 
lute mortality rate than patients randomized to placebo. After multivariable adjustment, 
all-cause mortality risks ware lower among patients with SDC a.8 (hazard ratio (HR] 
0.80, 95% Cl 0.68, 0.94), statistically comparable among patients with SDC 0.9 to 1 .I 
(HR 0.89. 95% Cl 0.74, 1.06), and trended toward increased harm among patients with 
SDC 21.2 (HR 1.16.95% Cl 0.96, 1.39) compared with patients randomized to placebo. 
Conclusions: Our findings suggest that the efficacy of digoxin therapy is optimized in 
the serum DIG concentration range of 0.5 ng/mL to 0.8 ng/mL among stable male hearl 
failure patients with left ventricular dysfunctidn. 
